Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task forceCindy Strehl, Frank Buttgereit, J. W. J. Bijlsma et al.|Annals of the Rheumatic Diseases|2016Cited by 331
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Raquel Celis, Hasan Rizvi et al.|The Lancet|2021Cited by 315